How Sleep and Breathing Affect Each Other

When obstructive sleep apnea (OSA) and COPD coexist in the same patient, the combination is called overlap syndrome. It affects an estimated 1–3.6% of the general population^[1] and a considerably higher proportion of patients seen in dedicated sleep or COPD clinics.

• Why it matters: Patients with overlap syndrome have more severe nocturnal oxygen desaturation, higher carbon dioxide levels, and greater cardiovascular risk (arrhythmias, pulmonary hypertension, heart failure) than patients with either condition alone.
• Symptoms: Excessive daytime sleepiness, morning headaches, unrefreshing sleep, and exertional breathlessness. The sleepiness of OSA and the breathlessness of COPD compound each other.
• Diagnosis: Requires both spirometry (showing airflow obstruction) and a sleep study (showing obstructive events). Overnight oximetry showing a "sawtooth" desaturation pattern can be a clue.
• Treatment: CPAP is the cornerstone of treatment for the OSA component — and has been shown to improve survival and reduce hospitalization for COPD exacerbations in overlap patients.^[2] Supplemental oxygen may be added if hypoxemia persists on CPAP. COPD medications (inhalers, pulmonary rehab) remain essential.

Learn more: Sleep Apnea · COPD

Asthma symptoms frequently worsen at night — a pattern called nocturnal asthma. Studies report that 50–75% of asthma patients experience nighttime symptoms at least once per week,^[3] and nighttime asthma attacks are a major cause of sleep disruption.

• Why asthma worsens at night: Circadian changes in airway tone, increased vagal (parasympathetic) activity, lower cortisol and epinephrine levels, supine position increasing airway secretions, late-phase allergic responses, and gastroesophageal reflux (which peaks when lying flat).
• OSA and asthma: A meta-analysis found the prevalence of OSA in adult asthma patients to be approximately 50%, with about 2.6 times higher odds compared to controls.^[4] OSA can worsen asthma control through reflux, upper airway inflammation, and systemic inflammation. Treating OSA with CPAP has been shown to improve asthma quality of life and reduce exacerbation frequency.^[5]
• Insomnia and asthma: Asthma-related coughing, wheezing, and breathlessness fragment sleep. Over time, this can lead to chronic insomnia that persists even when asthma is controlled.
• Management: Optimizing asthma controller therapy (especially evening dosing of ICS/LABA), controlling triggers in the bedroom (dust mites, pet dander), elevating the head of bed for reflux, and screening for OSA in patients with poorly controlled asthma.

Learn more: Asthma

Sleep disturbance is extremely common in interstitial lung disease (including pulmonary fibrosis) but often overlooked. Studies show 50–70% of ILD patients report poor sleep quality.

• Nocturnal hypoxemia: ILD patients have reduced gas exchange capacity (low DLCO). During sleep — when ventilation naturally decreases — oxygen levels can drop significantly, especially during REM sleep. This can occur even when daytime oxygen levels are normal.
• Cough: Chronic dry cough, a hallmark of many forms of ILD, is a major cause of sleep disruption and is often worse when lying down.
• OSA in ILD: A meta-analysis of 17 studies found an overall OSA prevalence of 68% in ILD, with rates of approximately 71% in IPF specifically.^[6] The prevalence of OSA in IPF has been reported as 50–90% across individual studies.^[7] Possible mechanisms include traction on the upper airway from reduced lung volumes, corticosteroid use, and gastroesophageal reflux. PAP treatment is associated with improved outcomes in IPF patients with coexisting OSA.^[7]
• Supplemental oxygen: Overnight oximetry or a sleep study can identify nocturnal hypoxemia requiring supplemental oxygen during sleep.
• Quality of life: Poor sleep in ILD is independently associated with worse quality of life, greater fatigue, and higher rates of depression and anxiety.

Learn more: Pulmonary Fibrosis

Sleep-disordered breathing is common in pulmonary hypertension (PH) and can worsen the hemodynamic burden on the right heart.

• OSA as a cause of PH: Chronic intermittent hypoxemia from untreated OSA can lead to pulmonary vasoconstriction and Group 3 pulmonary hypertension. A meta-analysis found a pooled OSA prevalence of 34% in PH patients overall.^[8] Treatment of OSA with CPAP can improve pulmonary artery pressures in these patients.
• Sleep-disordered breathing in PAH: Sleep-disordered breathing is common in pulmonary arterial hypertension (Group 1 PAH), with one retrospective study finding SDB in the majority of patients referred for polysomnography.^[9] Both obstructive and central sleep apnea can occur, likely driven by low cardiac output and prolonged circulation time.
• Nocturnal hypoxemia: PH patients are vulnerable to oxygen desaturation during sleep, which further raises pulmonary pressures and stresses the right ventricle.
• Clinical implications: A sleep study should be considered in PH patients with excessive sleepiness, observed apneas, or unexplained worsening of right heart function. Treatment depends on the mechanism — CPAP for OSA, oxygen for isolated nocturnal hypoxemia, and optimization of PH-specific therapy.

Learn more: Pulmonary Hypertension

Obesity hypoventilation syndrome is defined by the combination of obesity (BMI ≥ 30), daytime hypercapnia (elevated CO₂), and sleep-disordered breathing — in the absence of another cause of hypoventilation.^[10]

• Mechanism: Excess weight on the chest wall and abdomen restricts lung expansion. Combined with reduced central ventilatory drive, this leads to chronic carbon dioxide retention that worsens during sleep.
• Overlap with OSA: About 90% of OHS patients also have OSA, with the remaining 10% having sleep-related hypoventilation without significant obstruction.^[10] However, OHS is a distinct entity — it involves daytime respiratory failure, not just nighttime obstruction.
• Consequences: OHS carries significantly higher morbidity and mortality than OSA alone: pulmonary hypertension, right heart failure (cor pulmonale), polycythemia, and increased hospitalization rates.
• Diagnosis: An arterial blood gas showing daytime PaCO₂ ≥ 45 mmHg in an obese patient with sleep-disordered breathing (and no other cause of hypoventilation). A venous or serum bicarbonate level ≥ 27 mEq/L is a useful screening tool — in one study, this threshold had 92% sensitivity for identifying hypercapnia.^[11]
• Treatment: PAP therapy is the cornerstone: CPAP may be sufficient if OSA is the dominant component; bilevel PAP (BiPAP) is needed when hypoventilation persists. Weight loss is critical and can be curative. Some patients require supplemental oxygen in addition to PAP.

Some patients experience significant drops in oxygen during sleep even without obstructive sleep apnea. This is called isolated nocturnal hypoxemia or sleep-related hypoxemia.

• Causes: COPD (most common), interstitial lung disease, obesity/OHS, neuromuscular disease (diaphragm weakness), chest wall deformity, and high altitude.
• Why it happens without apnea: During sleep, decreased ventilatory drive and reduced functional residual capacity lower baseline oxygen levels. In patients with already-limited pulmonary reserve, these normal changes push oxygen below the threshold for desaturation.
• REM-related desaturation: REM sleep produces the most significant oxygen drops because diaphragmatic function is the only respiratory muscle group preserved (intercostal and accessory muscles are atonic). Patients with diaphragm weakness or severe COPD are especially vulnerable.
• Evaluation: Overnight oximetry or polysomnography can quantify the duration and severity of nocturnal hypoxemia. An arterial blood gas and pulmonary function tests help identify the underlying cause.
• Treatment: Supplemental oxygen during sleep is prescribed when sustained nocturnal desaturation is documented. The optimal flow rate is typically titrated during a sleep study. In neuromuscular disease, non-invasive ventilation (BiPAP) may be more appropriate than oxygen alone.

Neuromuscular diseases — including ALS, muscular dystrophies, myasthenia gravis, and diaphragm paralysis — frequently cause sleep-disordered breathing, often as the earliest sign of respiratory involvement.

• Why sleep is affected first: Respiratory muscle weakness may be compensated during wakefulness by accessory muscle use. During sleep (especially REM), accessory muscles become atonic, and breathing depends entirely on the diaphragm. A weakened diaphragm cannot maintain adequate ventilation, leading to hypoventilation and hypoxemia.
• Symptoms: Orthopnea (breathlessness when lying flat) is a classic early symptom. Others include morning headaches, fatigue, fragmented sleep, and daytime hypersomnia.
• Diagnosis: Sleep study with CO₂ monitoring, pulmonary function testing (FVC supine vs. upright — a drop of >20% suggests diaphragm weakness), and maximal respiratory pressures (MIP/MEP).
• Treatment: Non-invasive ventilation (typically BiPAP) during sleep is the standard of care and has been shown to improve quality of life and survival in conditions like ALS.^[12] Timing of initiation depends on symptoms, FVC trajectory, and sleep study findings.

Several commonly prescribed medications can affect the interaction between sleep and breathing.

• Opioids: Suppress ventilatory drive and can cause central sleep apnea, irregular breathing patterns (ataxic breathing), and severe nocturnal hypoxemia. The risk is dose-dependent and compounds with OSA.
• Benzodiazepines and sedative-hypnotics: Reduce upper airway muscle tone and blunt arousal responses, potentially worsening OSA severity. Should be used cautiously in patients with OSA or chronic lung disease.
• Beta-blockers: Can worsen bronchospasm in asthma/COPD and may contribute to sleep disturbance including nightmares and insomnia.
• Systemic corticosteroids: Commonly cause insomnia, and chronic use promotes weight gain and upper airway edema, both of which can worsen OSA.
• Theophylline: A bronchodilator that can cause insomnia and reduce sleep quality, particularly at higher serum levels.
• Supplemental oxygen: While essential for hypoxemia, supplemental oxygen without PAP therapy can sometimes worsen hypercapnia in patients with COPD or OHS by reducing hypoxic ventilatory drive.